R&D How automation can drive a competitive advantage for CROs & ... For CROs and CDMOs, automation is key to ensuring long-term success.
R&D Saudi pharma’s rise as a global CDMO destination: Investment... Saudi Arabia is steadily establishing itself as a competitive worldwide destination for contract development and manufacturing.
News Oxford BioMedica confirms private equity takeover talks Oxford BioMedica confirmed this morning that it has received an unsolicited approach from private equity group EQT about a possible takeover.
R&D CDMOs: Their crucial role and how to select one, with Sigma ... Sigma Mostafa, CSO at KBI BioPharma, discusses the role of CDMOs and the important factors companies should consider when selecting one.
R&D Seamless scale-up: Integrated manufacturing becomes the biop... Today, the demand for speed, quality, and scalability is pushing the industry towards a different model: integrated manufacturing.
News J&J earmarks $2bn for facility in North Carolina Johnson & Johnson has filled in some of the detail in its $55 billion investment in US facilities announced earlier this year.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
